Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique

More than half of lung cancers are discovered at an advanced stage. New anticancer treatments called personalized or targeted therapies have been introduced for non-small cell lung cancer (NSCLC), in association or in addition to classical chemotherapy. Personalized therapy includes tyrosine kinase inhibitors (TKI), antiangiogenic treatments, and immunotherapy. As these therapies are responsible for particular complications and atypical response as compared to classical chemotherapy, RECIST 1.1 criteria are often inadequate to properly evaluate the response to these therapies. We review the thoracic complications and therapy-specific tumor response as well as proposed personalized tumor response assessment.